Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Passage BIO ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Passage BIO's ebitda for the twelve months ending Sep 30, 2026 was -$34.98M. For fiscal 2025 it was -$48.57M. The highest annual figure on record is -$37.06M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.57M | – |
| FY2024 | Dec 31, 2024 | -$67.32M | – |
| FY2023 | Dec 31, 2023 | -$104.67M | – |
| FY2022 | Dec 31, 2022 | -$134.72M | – |
| FY2021 | Dec 31, 2021 | -$184.19M | – |
| FY2020 | Dec 31, 2020 | -$112.10M | – |
| FY2019 | Dec 31, 2019 | -$37.06M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$4.94M | – |
| Q2 FY2026 | Jun 30, 2026 | -$8.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.67M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.63M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$41.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$46.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$38.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$38.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.60M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.73M | – |
See a number that looks wrong?